Details of the Drug

General Information of Drug (ID: DMQ2491)

Drug Name

Nitroglycerin

Synonyms

nitroglycerin; Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Nitro-dur (TN); Transderm-nitro (TN); DWP-401

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Approved	[1], [2]
Diabetic foot ulcer	BD54	Approved	[3]

Therapeutic Class

Vasodilator Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

227.09

Topological Polar Surface Area (xlogp)

1.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 194.3 mL/min/kg [5]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 4.5 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.6356 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.4% [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.8 mg/mL [4]

Chemical Identifiers

Formula: C3H5N3O9
IUPAC Name: 1,3-dinitrooxypropan-2-yl nitrate
Canonical SMILES: C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]
InChI: InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
InChIKey: SNIOPGDIGTZGOP-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4510
ChEBI ID: CHEBI:28787
CAS Number: 55-63-0
DrugBank ID: DB00727
TTD ID: D07YDE
ACDINA ID: D00476

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Activator	[3]
Soluble guanylate cyclase (GCS)	TT23PYC	GCYA1_HUMAN; GCYB1_HUMAN	Modulator	[7], [8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Angina pectoris

ICD Disease Classification

BA40

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Epidermal growth factor receptor (EGFR)	DTT	EGFR	5.84E-05	0.32	0.55

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Nitroglycerin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Scopolamine	DMOM8AL	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Scopolamine.	Addictive disorder [6C50-6C5Z]	[20]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Cariprazine.	Bipolar disorder [6A60]	[21]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Selegiline.	Depression [6A70-6A7Z]	[22]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Isocarboxazid.	Depression [6A70-6A7Z]	[22]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Tranylcypromine.	Depression [6A70-6A7Z]	[22]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and OPC-34712.	Depression [6A70-6A7Z]	[21]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Phenelzine.	Depression [6A70-6A7Z]	[22]
Mepenzolate	DM8YU2F	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Mepenzolate.	Digestive system disease [DE2Z]	[20]
Oxybutynine	DMJPBAX	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Oxybutynine.	Discovery agent [N.A.]	[20]
Meclizine	DMS7T13	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Meclizine.	Dizziness and giddiness [MB48]	[20]
Solifenacin	DMG592Q	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Solifenacin.	Functional bladder disorder [GC50]	[20]
Tolterodine	DMSHPW8	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Tolterodine.	Functional bladder disorder [GC50]	[20]
Propantheline	DM2EN6G	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Propantheline.	Gastric ulcer [DA60]	[20]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Procarbazine.	Hodgkin lymphoma [2B30]	[22]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Captopril.	Hypertension [BA00-BA04]	[23]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Perindopril.	Hypertension [BA00-BA04]	[23]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Quinapril.	Hypertension [BA00-BA04]	[23]
Belladonna	DM2RBWK	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Belladonna.	Infectious gastroenteritis/colitis [1A40]	[20]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Propiomazine.	Insomnia [7A00-7A0Z]	[21]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and ITI-007.	Insomnia [7A00-7A0Z]	[21]
Clidinium	DMUMQZ0	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Clidinium.	Irritable bowel syndrome [DD91]	[20]
Dicyclomine	DMZSDGX	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Dicyclomine.	Irritable bowel syndrome [DD91]	[20]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Ozanimod.	Multiple sclerosis [8A40]	[22]
Dimenhydrinate	DM264B3	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Dimenhydrinate.	Nausea/vomiting [MD90]	[20]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Promethazine.	Nausea/vomiting [MD90]	[21]
Cyclizine	DM9G7BS	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Cyclizine.	Nausea/vomiting [MD90]	[20]
Prilocaine	DMI7DZ2	Major	Increased risk of methemoglobinemia by the combination of Nitroglycerin and Prilocaine.	Pain [MG30-MG3Z]	[24]
Flavoxate	DMKV4NL	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Flavoxate.	Pain [MG30-MG3Z]	[20]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Safinamide.	Parkinsonism [8A00]	[22]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Rasagiline.	Parkinsonism [8A00]	[22]
Biperiden	DME78OA	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Biperiden.	Parkinsonism [8A00]	[20]
Methylscopolamine	DM5VWOB	Minor	Decreased dissolution of Nitroglycerin taken sublingually caused by Methylscopolamine.	Peptic ulcer [DA61]	[20]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[21]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Quetiapine.	Schizophrenia [6A20]	[21]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Mesoridazine.	Schizophrenia [6A20]	[21]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Aripiprazole.	Schizophrenia [6A20]	[21]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Iloperidone.	Schizophrenia [6A20]	[21]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Paliperidone.	Schizophrenia [6A20]	[21]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Perphenazine.	Schizophrenia [6A20]	[21]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Molindone.	Schizophrenia [6A20]	[21]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Thiothixene.	Schizophrenia [6A20]	[21]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Trifluoperazine.	Schizophrenia [6A20]	[21]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Risperidone.	Schizophrenia [6A20]	[21]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Amisulpride.	Schizophrenia [6A20]	[21]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Asenapine.	Schizophrenia [6A20]	[21]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[21]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Nitroglycerin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[25]
-----------


⏷ Show the Full List of 47 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Acetylated sucrose distearate	E00592	71587451	Emollient
Allura red AC dye	E00338	33258	Colorant
D&C red no. 22	E00206	11048	Colorant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Glyceryl monostearate	E00310	24699	Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Quinoline yellow WS	E00309	24671	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate	E00244	15324	lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
FD&C red no. 3	E00629	Not Available	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 23 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Nitroglycerin 9 mg capsule	9 mg	Extended Release Oral Capsule	Oral
Nitroglycerin 2.5 mg capsule	2.5 mg	Extended Release Oral Capsule	Oral
Nitroglycerin 6.5 mg capsule	6.5 mg	Extended Release Oral Capsule	Oral
Nitroglycerin 0.3 mg tablet	0.3 mg	Sublingual Tablet	Oral
Nitroglycerin 0.4 mg tablet	0.4 mg	Sublingual Tablet	Oral
Nitroglycerin 300 mcg tablet	300 mcg	Sublingual Tablet	Oral
Nitroglycerin 400 mcg tablet	400 mcg	Sublingual Tablet	Oral
Nitroglycerin 600 mcg tablet	600 mcg	Sublingual Tablet	Oral
Nitroglycerin 0.6 mg tablet	0.6 mg	Sublingual Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7053).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018531.
3	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
4	BDDCS applied to over 900 drugs
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14.
8	Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Crit Care Res Pract.2012;2012:290805.
9	Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol. 1996 May 30;77(13):2C-7C.
10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11	Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
12	Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
13	Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
14	Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
15	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
16	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
17	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
18	Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
19	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
20	Product Information. Nitrostat (nitroglycerin). Parke-Davis, Morris Plains, NJ.
21	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
22	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
23	Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7. [PMID: 1901528]
24	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
25	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.